Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Schenk

Showing results (81-90 of 102) with videos related to

Pageof 11
Sort By:
Investigational New Drugs|September 13, 2021
Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignanciesJoleen M Hubbard, Jun Yin, Erin L Schenk, et al.
Clinical Lung Cancer|May 28, 2026
High Programmed Death-Ligand 1 Expression is Associated With a Shorter Progression Free Survival in ALK-Rearranged Lung Cancer Patients Treated With First Line Tyrosine Kinase InhibitorsYunan Nie, Alyse Staley, Trista K Hinz, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 15, 2014
Diverse mutational pathways converge on saturable chloroquine transport via the malaria parasite's chloroquine resistance transporterRobert L Summers, Anurag Dave, Tegan J Dolstra, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 18, 2020
Cancer Cell-Intrinsic Expression of MHC Class II Regulates the Immune Microenvironment and Response to Anti-PD-1 Therapy in Lung AdenocarcinomaAmber M Johnson, Bonnie L Bullock, Alexander J Neuwelt, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 13, 2019
A Randomized Double-Blind Phase II Study of the Seneca Valley Virus (NTX-010) versus Placebo for Patients with Extensive-Stage SCLC (ES SCLC) Who Were Stable or Responding after at Least Four Cycles of Platinum-Based Chemotherapy: North Central Cancer Treatment Group (Alliance) N0923 StudyErin L Schenk, Sumithra J Mandrekar, Grace K Dy, et al.
Regulatory Toxicology and Pharmacology : RTP|August 14, 2020
Reflections on the OECD guidelines for in vitro skin absorption studiesN B Hopf, C Champmartin, L Schenk, et al.
Lung Cancer (Amsterdam, Netherlands)|November 30, 2024
The efficacy of continuing osimertinib with platinum pemetrexed chemotherapy upon progression in patients with metastatic non-small cell lung cancer harboring sensitizing EGFR mutationsTejas Patil, Dexiang Gao, Alexander Watson, et al.
Life Science Alliance|May 29, 2019
Tumor-intrinsic response to IFNγ shapes the tumor microenvironment and anti-PD-1 response in NSCLCBonnie L Bullock, Abigail K Kimball, Joanna M Poczobutt, et al.
Theriogenology|August 17, 2010
Large-scale in vitro embryo production and pregnancy rates from Bos taurus, Bos indicus, and indicus-taurus dairy cows using sexed spermJ H F Pontes, K C F Silva, A C Basso, et al.
Nature Medicine|June 13, 2018
DNA repair processes are critical mediators of p53-dependent tumor suppressionAna Janic, Liz J Valente, Matthew J Wakefield, et al.
Pageof 11

Showing results (81-90 of 102) with videos related to

Sort By:
Pageof 11
Investigational New Drugs|September 13, 2021
Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignanciesJoleen M Hubbard, Jun Yin, Erin L Schenk, et al.
Clinical Lung Cancer|May 28, 2026
High Programmed Death-Ligand 1 Expression is Associated With a Shorter Progression Free Survival in ALK-Rearranged Lung Cancer Patients Treated With First Line Tyrosine Kinase InhibitorsYunan Nie, Alyse Staley, Trista K Hinz, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 15, 2014
Diverse mutational pathways converge on saturable chloroquine transport via the malaria parasite's chloroquine resistance transporterRobert L Summers, Anurag Dave, Tegan J Dolstra, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 18, 2020
Cancer Cell-Intrinsic Expression of MHC Class II Regulates the Immune Microenvironment and Response to Anti-PD-1 Therapy in Lung AdenocarcinomaAmber M Johnson, Bonnie L Bullock, Alexander J Neuwelt, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 13, 2019
A Randomized Double-Blind Phase II Study of the Seneca Valley Virus (NTX-010) versus Placebo for Patients with Extensive-Stage SCLC (ES SCLC) Who Were Stable or Responding after at Least Four Cycles of Platinum-Based Chemotherapy: North Central Cancer Treatment Group (Alliance) N0923 StudyErin L Schenk, Sumithra J Mandrekar, Grace K Dy, et al.
Regulatory Toxicology and Pharmacology : RTP|August 14, 2020
Reflections on the OECD guidelines for in vitro skin absorption studiesN B Hopf, C Champmartin, L Schenk, et al.
Lung Cancer (Amsterdam, Netherlands)|November 30, 2024
The efficacy of continuing osimertinib with platinum pemetrexed chemotherapy upon progression in patients with metastatic non-small cell lung cancer harboring sensitizing EGFR mutationsTejas Patil, Dexiang Gao, Alexander Watson, et al.
Life Science Alliance|May 29, 2019
Tumor-intrinsic response to IFNγ shapes the tumor microenvironment and anti-PD-1 response in NSCLCBonnie L Bullock, Abigail K Kimball, Joanna M Poczobutt, et al.
Theriogenology|August 17, 2010
Large-scale in vitro embryo production and pregnancy rates from Bos taurus, Bos indicus, and indicus-taurus dairy cows using sexed spermJ H F Pontes, K C F Silva, A C Basso, et al.
Nature Medicine|June 13, 2018
DNA repair processes are critical mediators of p53-dependent tumor suppressionAna Janic, Liz J Valente, Matthew J Wakefield, et al.
Pageof 11